Comparison of the costs of HPV testing through community health campaigns versus home-based testing in rural Western Kenya: a microcosting study. Issue 10 (27th October 2020)

• Record Type: Journal Article
• Authors: Olwanda, Easter Elizabeth; Kahn, James G; Choi, Yujung; Islam, Jessica Yasmine; Huchko, Megan
• Is Part Of: BMJ open. Volume 10:Issue 10(2020)
• Publication Date: 2020-10-27
• Subjects: cervical cancer -- human papillomavirus -- community health campaigns -- home-based testing -- micro-costing -- rural Kenya; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-033979
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: To estimate the cost of human papillomavirus (HPV)-based screening through community health campaigns (CHCs) and home-based testing. Setting: CHCs and home-based testing in six communities in rural Western Kenya. Participants: CHCs and home-based screening reached 2297 and 1002 women aged 25–65 years, respectively. Outcome measures: Outcome measures were overall cost per woman screened achieved through the CHCs and home-based testing and the cost per woman for each activity comprising the screening intervention. Results: The mean cost per woman screened through CHCs and home-based testing were similar, at $37.7 (range $26.4–$52.0) and $37.1 (range $27.6–$54.0), respectively. For CHCs, personnel represented 49% of overall cost, supplies 25%, services 5% and capital goods 23%. For home-based testing, these were: personnel 73%, supplies 25%, services 1% and capital goods 2%. A greater number of participants was associated with a lower cost per participant. Conclusions: The mean cost per woman screened is comparable for CHC and home-based testing, with differences in type of input. The CHCs generally reached more eligible women in the six communities, whereas home-based strategies more efficiently reached populations with low screening rates. Trial registration number: NCT02124252 .